Psoriasis in children frequently manifests on visible areas like the face and scalp, often leading to social stigma, school absenteeism, and an increased risk of long-term comorbidities. Despite this burden, roughly 70 percent of pediatric patients currently rely on topical therapies alone. This new indication provides a systemic treatment option for those who are candidates for such therapy, filling a critical gap in pediatric dermatology.

The regulatory decision follows data from the OptIMMize-1 and OptIMMize-2 trials, which evaluated the safety and efficacy of the IL-23 inhibitor across two age cohorts: six to 12 years and 12 to 18 years. Clinical results showed a safety profile consistent with adult data, with no new signals identified among the 137 pediatric participants. By enabling weight-based dosing, the new 55 mg syringe allows physicians to tailor treatment for patients weighing less than 40 kg, improving the precision of care for a population where early management is vital to preventing disease progression.